Dynavax Technologies (DVAX) News Today

Dynavax Technologies Corporation (DVAX) shares are rallying as investors digest a suite of upbeat earnings reports and a bullish analyst upgrade. The biopharma firm posted strong Q2 results—beating revenue and EPS estimates, delivering record HEPLISAV-B® sales, and tightening full-year guidance—while JMP Securities lifted its target and reiterated a “market outperform” view.

• Positive Sentiment: JMP Securities raised its target price on DVAX from $31 to $32 with a “market outperform” rating, implying over 200% upside. Benzinga
• Positive Sentiment: Dynavax reported record HEPLISAV-B® quarterly net product revenue of $92 million, up 31% year-over-year, and raised its 2025 guidance range to $315–325 million. PR Newswire
• Positive Sentiment: Q2 earnings exceeded expectations, with EPS of $0.14 vs. $0.12 consensus and revenue of $95.44 million vs. $87.55 million forecast. Zacks
• Positive Sentiment: Q2 revenue jumped 29% year-over-year, underscoring strong top-line momentum. Fool
• Positive Sentiment: TipRanks highlights Dynavax’s “strong Q2 2025 results” as a key positive catalyst for the stock. TipRanks
• Neutral Sentiment: A strategic SWOT analysis outlines DVAX’s strengths, weaknesses, opportunities, and threats. GuruFocus
• Neutral Sentiment: The full Q2 2025 earnings call transcript provides management commentary on performance and pipeline progress. Seeking Alpha Transcript
• Neutral Sentiment: Presentation slides from the Q2 earnings call detail financials and clinical updates. Seeking Alpha Presentation